Handbook of Clinical medicine
KEYWORDS: patient, disease, patients, history, pain, heart, symptoms, ask, time, treatment, risk, examination, aortic, iinnddbb, pulse

pyridoxine) and rifampicin OR 6 months of isoniazid (with pyridoxine). If concerns about hepatotoxicity then 3 months of isoniazid and rifampicin may be preferred. In severe liver disease, seek specialist advice. If interactions with rifamy- cins are a concern (eg HIV, transplant) then 6 months of isoniazid may be preferred. Active TB All forms of active TB are statutorily notifi able in UK. This includes both clinical and culture diagnoses. Notifi cation is via your local public health protection team (www. gov.uk/health-protection-team).Treatment is given under the care of a specialist TB clini- cian/service according to table 9.10. Exceptions include: • active CNS disease (including spinal cord involvement): continuation phase of treat- ment is extended from 4 to 10 months • CNS and pericardial disease: use adjunctive high-dose steroids (with weaning and withdrawal during the intensive treatment period) • drug-resistant TB. Adherence is important for treatment to be eff ective and to prevent drug resistance. Directly observed therapy (DOT) should be considered if: previous treatment for TB, homelessness, drug/alcohol misuse, prison, psychiatric or cognitive disorder, multi- drug resistant disease, patient request. Universal access to diagnosis and treatment of TB is part of social justice. WHO has developed an ‘End TB’ strategy
